RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 6, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-11-19
DOI
10.1186/s40425-018-0438-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
- (2018) Franck Pagès et al. LANCET
- CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis
- (2018) James Ziai et al. PLoS One
- PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
- (2018) Magalie Dosset et al. OncoImmunology
- Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival
- (2017) Bernhard Mlecnik et al. JNCI-Journal of the National Cancer Institute
- Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival
- (2017) Bernhard Mlecnik et al. JNCI-Journal of the National Cancer Institute
- QuPath: Open source software for digital pathology image analysis
- (2017) Peter Bankhead et al. Scientific Reports
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983
- (2015) Erik Tanis et al. EUROPEAN JOURNAL OF CANCER
- Prognostic value of HLA class I expression in patients with colorectal cancer
- (2015) Yuji Iwayama et al. World Journal of Surgical Oncology
- Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
- (2014) M.-G. Anitei et al. CLINICAL CANCER RESEARCH
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
- (2013) Jérôme Galon et al. JOURNAL OF PATHOLOGY
- Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
- (2013) Bernard Nordlinger et al. LANCET ONCOLOGY
- Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration
- (2013) Niels Halama et al. OncoImmunology
- Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases
- (2010) D. A. Wicherts et al. BRITISH JOURNAL OF SURGERY
- Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review
- (2010) Katsuhiko Nosho et al. JOURNAL OF PATHOLOGY
- In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
- (2009) Franck Pagès et al. JOURNAL OF CLINICAL ONCOLOGY
- The essential role of the in situ immune reaction in human colorectal cancer
- (2008) Franck Pagès et al. JOURNAL OF LEUKOCYTE BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now